On Wednesday, July 27th in Toronto, T3D Therapeutics will present Preliminary Results of a 36-patient, two-week Phase 2a Open Label Feasibility Clinical Trial, showing Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated with T3D-959
Recent Posts
- T3D Therapeutics Selected to Present Topline Results from the Phase 2 PIONEER Study of T3D-959 as Late Breaking News at the 16th Clinical Trials on Alzheimer’s Disease Conference (CTAD)
- T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease
- T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
- Alzheimer’s Association Part The Cloud Grant Program Invests $24 Million in 16 Innovative Research Trials
- Leading Alzheimer’s Disease Experts Join T3D Therapeutics’ Scientific Advisory Board